for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vectura Group PLC

VEC.L

Latest Trade

111.60GBp

Change

-0.20(-0.18%)

Volume

201,571

Today's Range

110.00

 - 

112.60

52 Week Range

59.10

 - 

124.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
111.80
Open
110.00
Volume
201,571
3M AVG Volume
25.37
Today's High
112.60
Today's Low
110.00
52 Week High
124.80
52 Week Low
59.10
Shares Out (MIL)
595.88
Market Cap (MIL)
665.01
Forward P/E
23.47
Dividend (Yield %)
--

Latest Developments

More

Vectura Group Signs Development Agreement With Kinaset Therapeutics For Treatment Of Asthama

Vectura Says U.S. Court Denies GSK's Motions In Litigation Concerning Co's U.S. Patent

Hikma Gets USFDA Minor Complete Response Letter For Generic Version Of GlaxoSmithKline's Advair Diskus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Industry

Biotechnology & Drugs

Contact Info

Unit 1, Prospect West, Bumpers Way

SN14 6FH

United Kingdom

+44.1249.667700

http://www.vectura.com

Executive Leadership

Bruno F. J. Angelici

Non-Executive Chairman of the Board

William Downie

Chief Executive Officer, Executive Director

Paul Fry

Chief Financial Officer, Executive Director

Joanne Hombal

Executive Vice President of Human Resources

Antony Fitzpatrick

Executive Vice President – Operations

Key Stats

1.29 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.1K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (GBp)

2017

4.507

2018

4.236

2019

5.690

2020(E)

4.753
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.77
Price To Book (MRQ)
1.54
Price To Cash Flow (TTM)
22.93
Total Debt To Equity (MRQ)
1.98
LT Debt To Equity (MRQ)
1.65
Return on Investment (TTM)
-1.43
Return on Equity (TTM)
-1.28

Latest News

Latest News

BRIEF-Vectura Group Says Enerzair Breezhaler Gets Regulatory Nod

* VECTURA GROUP PLC - ENERZAIR® BREEZHALER® RECEIVES REGULATORY APPROVAL

BRIEF-Vectura Group Signs Global Licence And Development Agreement With Aerami Therapeutics

* VECTURA GROUP PLC - SIGNING OF A GLOBAL LICENCE AND DEVELOPMENT AGREEMENT WITH AERAMI THERAPEUTICS

BRIEF-Vectura Group Maintains 2020 Outlook

* VECTURA GROUP PLC - AGM TRADING UPDATE & REITERATION OF 2020 GUIDANCE

BRIEF-Vectura Says Upon European Regulatory Approval Of QVM149, Eligible To Get $5 Mln Milestone

* FINAL DECISION FROM EUROPEAN COMMISSION FOR GRANT OF MARKETING AUTHORISATION EXPECTED BE RECEIVED ABOUT 2 MONTHS AFTER CHMP OPINION

BRIEF-Vectura Says It Has Not Seen Any Impact To Its Business From Covid-19

* VECTURA GROUP PLC - AT THIS TIME, VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM COVID-19

BRIEF-Vectura Group FY Gross Profit 95.3 Mln Stg Vs 98.9 Mln Stg

* VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM THE CORONAVIRUS OUTBREAK

Vectura, Sandoz win ruling on inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Drugmaker Vectura parts ways with CEO Ward-Lilley

British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

Drugmaker Vectura CEO James Ward-Lilley to step down

British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.

BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission

* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

Vectura hopes new respiratory device will breathe life into business

Vectura Group <VEC.L> is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

UK drugmaker Vectura expects 2018 earnings to top market forecasts

British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

Vectura to stop developing asthma treatment after late-stage failure

British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

UPDATE 1-Vectura reviewing drug stockpiles as no-deal Brexit looms

British drugmaker Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its mitigation plan for a "no-deal" Brexit and warned on Tuesday of a potential disruption to supply chains and higher costs.

Vectura reviewing drug stockpiles as no-deal Brexit looms

Vectura Group Plc is reviewing its stockpiles of drugs and key components as part of its plan for a "no-deal" Brexit, the British drugmaker said on Tuesday, and warned of a potential disruption to supply chains and higher costs.

BRIEF-Sosei Says Does Not Intend To Make An Offer For Vectura

* CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA

BRIEF-Vectura Says CFO Decided To Leave Group

* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up